Literature DB >> 9406045

Reproductive safety of melatonin: a "wonder drug" to wonder about.

D R Weaver1.   

Abstract

By some accounts, melatonin is the wonder drug of the 1990s. This previously obscure hormone came to the public's full attention as the result of a series of popular books claiming therapeutic benefits of melatonin ingestion. Some of these claims deserve serious consideration and investigation, whereas others appear unfounded. Without waiting for the outcome of the ongoing scientific debate, however, melatonin set astounding sales records. The hormone is now ingested on a daily basis by many thousands of people. There is little information on the potential adverse effects of melatonin ingestion in humans. Melatonin, its analogs, and its metabolites are not mutagenic, and melatonin possesses remarkably low acute toxicity in animals and humans. It is more difficult to exclude toxic effects of long-term melatonin treatment. The fact that melatonin is normally secreted each night does not ensure that exogenous melatonin, taken at other times and/or in supraphysiological doses, will not have adverse effects. Despite the well-recognized role of melatonin in the regulation of reproduction in photoperiodic species, it seems unlikely that chronic ingestion of moderate melatonin doses will have a profound impact on reproductive function in humans. Evidence that melatonin modulates steroid hormone action in some steroid-responsive tissues suggests that these tissues should be carefully examined when attempting to assess whether melatonin has chronic toxicity in humans. In the absence of sufficient information regarding the longterm safety of exogenous melatonin, the conservative course of action is to restrict melatonin use to those therapeutic applications in which a significant benefit is expected. The decision to ingest melatonin should be preceded by careful consideration of the expected benefits as well as the potential costs of treatment, with recognition of the fact that there has been exaggeration of the benefits and little attention paid to the potential costs in most discussions of this issue to date.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9406045     DOI: 10.1177/074873049701200625

Source DB:  PubMed          Journal:  J Biol Rhythms        ISSN: 0748-7304            Impact factor:   3.182


  6 in total

Review 1.  Sleep disorders in children.

Authors:  Oliveiero Bruni; Luana Novelli
Journal:  BMJ Clin Evid       Date:  2010-09-27

Review 2.  Medication for sleep-wake disorders.

Authors:  G Stores
Journal:  Arch Dis Child       Date:  2003-10       Impact factor: 3.791

Review 3.  Sleep disorders in children.

Authors:  Paul Montgomery; Danielle Dunne
Journal:  BMJ Clin Evid       Date:  2007-09-01

4.  Mapping of the Insomnia Severity Index and other sleep measures to EuroQol EQ-5D health state utilities.

Authors:  Ning Yan Gu; Marc F Botteman; Xiang Ji; Christopher F Bell; John A Carter; Ben van Hout
Journal:  Health Qual Life Outcomes       Date:  2011-12-30       Impact factor: 3.186

5.  A pilot double-blind randomised placebo-controlled dose-response trial assessing the effects of melatonin on infertility treatment (MIART): study protocol.

Authors:  Shavi Fernando; Tiki Osianlis; Beverley Vollenhoven; Euan Wallace; Luk Rombauts
Journal:  BMJ Open       Date:  2014-09-01       Impact factor: 2.692

Review 6.  Melatonin: shedding light on infertility?--A review of the recent literature.

Authors:  Shavi Fernando; Luk Rombauts
Journal:  J Ovarian Res       Date:  2014-10-21       Impact factor: 4.234

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.